The latest price target for Amylyx Pharma (NASDAQ:AMLX) was reported by HC Wainwright & Co. on December 5, 2024. The analyst firm set a price target for $12.00 expecting AMLX to rise to within 12 months (a possible 195.57% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Amylyx Pharma (NASDAQ:AMLX) was provided by HC Wainwright & Co., and Amylyx Pharma reiterated their buy rating.

The last upgrade for Amylyx Pharmaceuticals Inc happened on November 18, 2024 when Baird raised their price target to $11. Baird previously had a neutral for Amylyx Pharmaceuticals Inc.

The last downgrade for Amylyx Pharmaceuticals Inc happened on March 11, 2024 when Goldman Sachs changed their price target from $40 to $4 for Amylyx Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amylyx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amylyx Pharma was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Amylyx Pharma (AMLX) rating was a reiterated with a price target of $12.00 to $12.00. The current price Amylyx Pharma (AMLX) is trading at is $4.06, which is out of the analyst’s predicted range.